Recent developments in antidepressant agents

Progress in Drug Research

Volumn 46, Issue , 1996, Pages 243-262

  Claghorn, James ^a   Lesem, Michael D ^a  

^a Claghorn Lesem Research Clinic Ltd   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BUSPIRONE; DOPAMINE RECEPTOR; FLESINOXAN; IMIPRAMINE; MIRTAZAPINE; NEFAZODONE; ORG 4428; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG; VENLAFAXINE;

AGRANULOCYTOSIS; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; HALLUCINATION; HEADACHE; HUMAN; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; VERTIGO; XEROSTOMIA;

EID: 0029896627     PISSN: 0071786X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-0348-8996-4_6     Document Type: Review

References (73)

1. Practice guidelines for major depression disorders in adults. Am. J. Psychiatry (suppl) 150, 1-26 (1993).
2. Guze S., Robins E.: Suicide and primary affective disorders. Br. J. Psychiatry 117, 437-438 (1970).
3. Block R., Dooneieff A., Buchberg A., Spellman S.:The clinical effects of isoniazid and iproniazid in the treatment of pulmonary tuberculosis. Ann. Intern. Med. 40, 881-900 (1954).
4. Kline N.S.: Clinical experience with iproniazid (Marsilid). J. Clin. Exp. Psychopathol. 79 (suppl.), 72-78 (1958).
5. Potter W., Rudorfer M., Manji H.: The pharmacological treatment of depression. N. Engl. J. Med. 525, 633-642 (1991).
6. Baldessarini R.: Chemotherapy in Psychiatry. Harvard University Press, Cambridge 1985.
7. Kuhn R.: The treatment of depressive states with G22355 (imipramine hydrochloride). Am. J. Psychiatry 775, 459-464 (1958).
8. Potter W.Z.: Psychotherapeutic drugs and biogenic amines: Current concepts and therapeutic implications. Drugs 28, 127-43 (1984).
9. Richelson E.:The new antidepressants: Structures, pharmacokinetics, pharmacodynamics. and proposed mechanisms of action. Psychopharmacol. Bull. 20, 213-23 (1984).
10. Richelson E., Nelson A.: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J. Pharmacol. Exp. Ther. 230, 94-102 (1984).
11. Joyce P.R., Paykel E.S.: Predictors of drug response in depression. Arch. Gen. Psychiatry 46, 89-99 (1989).
12. Bech P.: A review of the antidepressant properties of serotonin re-uptake inhibitors. Adv. Biol. Psychiatry 17, 58-69 (1988).
13. Rudorfer M.V., Potter W.Z.: Antidepressants: A comparative review of the clinical pharmacology and therapeutic use of the "newer" versus the "older" drugs. Drugs 37, 713-38 (1989).
14. Richeison E.: The pharmacology of antidepressants at the synapse: Focus on newer compounds. J. Clin. Psychiatry 55, 9 (suppl. A) 34-39 (1994).
15. Clements-Jewery S., Robson P.A., Chidley L.J.: Biochemical investigations into the mode of action of trazodone. Neuropharmacology 19, 1165-1173 (1980).
16. Caccia S., Ballalio M., Samanin R. et al.: (-)M-chlorophenyl-piperazine, a central 5-hydroxytryptamine antagonist, is a metabolite of trazodone. J. Phar. Pharmacol. 33, 477-78 (1981).
17. Laizure S.C., Devane C.L., Stewart J.T. et al.: Pharmacokinetics of bupropion and its major basic metabolites in normal subject after a single dose. Clin. Pharmacol. Ther. 35, 586-589 (1985).
18. Perumal A., Smith T., Suckow R. et al.: Effect of plasm from patients containing bupropion and its metabolites on the up-take of norepinephrine. Neuropharmacology 25, 199-202 (1986).
19. Rudorfer M.V., Golden R.N., Potter W.Z.: Second Generation Antidepressants. Psychiatric Clin, of North Am. 7, 519-534 (1984).
20. Davidson M.: Seizures and bupropion: A review. J. Clin. Psychiatry 50, 256-261 (1989).
21. Grimsley S.R., Jann M.W: Paroxetine, sertraline, and fluvoxamine: New selective serotonin re-uptake inhibitors. Clin. Pharmacol. 2, 930-957 (1992).
22. Van Harten J.M.: Clinical pharmacokinetics of selective serotonin re-uptake inhibitors. Clin. Pharmacokinet. 24/3, 203-220 (1993).
23. Johnson A.M.: The comparative pharmacological properties of selective serotonin re-uptake inhibitors in animals. In: Selective Serotonin Re-Uptake Inhibitors. Feighner and Boyers (eds.), pp. 37-70. John Wiley & Sons, Chichester 1991.
24. Thomas D.R., Nelson D.R., Johnson A.M.: Biochemical effects of the antidepressant paroxetine. a specific 5-hydroxy-tryptamine uptake inhibitor. Psychopharmacology 93, 193-200 (1987).
25. Bergstrom R.F., Lemberger L., Farid N.A., Wolen R.L.: Clinical pharmacology and pharmacokinetics of fluoxetine: A review. Br. J. Psychiatry 153 (suppl. 3). 47-50 (1988a).
26. Benfield P., Heel R.C., Lewis S.P.: Fluoxetine: A review of its pharmacodynamic and pharmacokinetics properties and therapeutic efficacy in depressive illness. Drugs 32, 481-508 (1986).
27. HevmJ., Koe B.K.: Pharmacology of sertraline: A review. Clin. Psychiatry 495, 40-45 (1988).
28. Pages L.J., Garg D.C., Martinez J.J. et al.: Safety and pharmokinetics of sertraline in healthy young males. J. Clin. Pharmacological. 28, 920 (abstract) (1988).
29. Kay C.M., Haddock R.E., Langley P.F. et al.: A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr. Scand. 80 (suppl 350), 60-73 (1989).
30. Devane C.L.: Pharmacokinetics of the selective serotonin re-uptake inhibitors. J. Clin. Psychiatry 53/2 (suppl), 13-20 (1992).
31. Preskon S.H.: Pharmacokinetics of antidepressants: Why & How They are Relevant to Treatment. J. Clin. Psychiatry 54(9) (suppl), 14-34 (1993).
32. Greenblatt D.J.: Basic pharmacokinetic principles and their application to psychotropic drugs. J. Clin. Psychiatry 54(9) (suppl), 8-13 (1993).
33. Fleishaker J.C., Hulst L.K.: Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of alprazolam in healthy volunteers. Pharmacol. Res. 9 (suppl), S292 (1992).
34. Beasley C., Masica D.N., Heilegenstein J.A., Wheadon D.E., Zerve R.L.: Possible MAOI-SSRI interaction: Fluoxetine clinical data and preclinical findings. J. Clin. Psychiatry 75, 312-20 (1993).
35. Leonard B.E.: Comparative pharmacology of new antidepressants. J. Clin. Psychiatry 54, 8 (suppl), 3-15 (1993).
36. Tollefsan G.D.: Antidepressant treatments and side effect consideration. J. Clin. Psychiatry 52, 5 (suppl), 4-13 (1991).
37. Bech P:. Acute therapy of depression. J. Clin. Psychiatry 54, 8 (suppl) (1993).
38. Nievenberg A.A.: The treatment of severe depression: Is there an efficacy gap between SSRI and TCA antidepressant generations? J. Clin. Psychiatry 55, 9 (suppl. A) (1994).
39. Beasley C.M., Holman S.L., Potvin J.H.: Fluoxetine compared with imipramine in the treatment of inpatient depression: A multicenter trial. Ann. Clin. Psychiatry 5, 199-208 (1993).
40. Bowden C.L., Schatzberg A.F., Rosenbaum A. et al.: Fluoxetine and desipramine in major depressive disorder. J. Clin. Psychopharmacol. 13, 305-310 (1993).
41. Pande A., Sayler M.: Severity of depression and response to fluoxetine. Int. Clin. Psychopharmacol. 8, 243-245 (1993).
42. Report H. 128.112. Pharmacological properties of flesinoxan. The Netherlands: DuPhar, 1990, pp. 1-31.
43. Report H. 128.113. Pharmacological properties of flesinoxan. Effects on the central nervous system. The Netherlands: DuPhar, 1990, pp. 1-42.
44. Amsterdam J.D., Berwish N., Potter L., Rickeis K.: Open trial of gepirone in the treatment of major depressive disorder. Curr. Ther. Res. 47, 185-193 (1987).
45. 1a ligand with both antidepressant and anxiolytic activity. Psychopharmacol. Bull. 24, 164-167 (1988).
46. Schweizer E.E.,Amsterdam J., Rickels K., Kaplan M., Droba M.: Open trial of buspirone in the treatment of major depressive disorder. Psychopharmacol. Bull. 22, 183-185 (1986).
47. Report H. 128.6001. Pharmacokinetics of flesinoxan hydrochloride after single oral dosing in healthy volunteers. The Netherlands: DuPhar, No. H. 128.623.
48. Report H. 128.6002. Pharmacokinetics of flesinoxan hydrochloride in healthy volunteers after single intravenous infusion: A pilot study. DuPhar Report No. H. 128.630.
49. Report H. 128.5012.The effects of oral flesinoxan, placebo and buspirone in healthy male volunteers: A pharmaco EEG, safety and tolerance cross-over study (protocol H. 128.5012).
50. Report H. 128.5001. Disposition of the radioactivity of (14c)DU 29373 after oral administration to healthy male volunteers. DuPhar Report No. H. 128.611.
51. Report H. 128.5002. The effects of DU 29373 in healthy male volunteers. A randomized, double-blind, placebo-controlled, rising-singie-oral-dose study (protocol No. H. 128.5002/M).
52. Report H. 128.5003/M. The effects of DU 29373 in healthy male volunteers. A randomized, double-blind, oral placebo-controlled, cross-over study (protocol No. H. 128.5003/M).
53. Report H. 128.5009/A. Effects of oral flesinoxan in healthy volunteers. A randomized, double-blind, placebo-controlled pilot single-rising-dose study and multiple dose study. Part A: The singie-rising-dose study.
54. Report H. 128.5009B. Effects of oral flesinoxan in healthy volunteers. A randomized, double-blind, placebo-controlled pilot single-rising-dose study and multiple dose study. Part B:The multiple dose study.
55. Report H. 128.6007. The influence of different dose levels and multiple dosing of flesinoxan on its pharmacokinetics in healthy male subjects. An oral multiple-dose/dose-proportionality study).
56. Report H. 128.5004. Effects of oral flesinoxan in healthy male volunteers. A randomized, double-blind, placebo-controlled, multiple-dose study.
57. Report H. 128.5020. Oral flesinoxan and imipramine treatment in patients with major depressive disorder. A double-blind, placebo-controlled, multi-center study. The Netherlands: Solvay DuPhar, 1993, pp. 1-98.
58. Ruigt G.: Effects of ORG 4428 on the central and autonomic nervous systems - in vivo studies (SDG RR 3597).
59. Zandberg P., Santegoets W.: Cardiovascular effects in anesthetized cats (SDGRR 2729).
60. Altman J.F.B., Mant T.G.K.. Morrison P.J.: A phase I. double-blind, placebo-controlled, single-rising-oral-dose study with ORG 4428 in healthy male volunteers to assess its tolerance and safety as well as its pharmacokinetics profile (protocol 25801) Part I: Safety and tolerance at dose levels of 10, 25, 35, 50, 200, 350, 500, 750, and 1000 mg. SDG Release Report No. 3065. Part II: Pharmacokinetics profile of ORG 4428 after doses of 10-500 mg. SDG Release Report No. 3007.
61. Altman J.F.B., Mant T.G.K.. Morrison P.J.: A phase I. double-blind, placebo-controlled, single-rising-oral-dose study with ORG 4428 in healthy male volunteers to assess its tolerance and safety as well as its pharmacokinetics profile (protocol 25801) Part I: Safety and tolerance at dose levels of 10, 25, 35, 50, 200, 350, 500, 750, and 1000 mg. SDG Release Report No. 3065. Part II: Pharmacokinetics profile of ORG 4428 after doses of 10-500 mg. SDG Release Report No. 3007.
62. Mant T.G.K., Morrison P.J., Altman J.F.B.: A phase I, double-blind, placebo-controiled, multiple-dose study with ORG 4428 in healthy male volunteers to assess its tolerance and safety as well as its effects on EEG-monitored sleep characteristics (protocol 28502).
63. Sennef C., Kramer J.: Pilot efficacy studies in depressed hospitalized patients. SDG Release Report No. 3675.
64. Eison A.S., Eison M.S.,Torrente J.R., Wright R.N., Yocca F.D.: Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull. 26, 311-315 (1990).
65. Fontaine R.: Novel serotonergic mechanisms and clinical experience with nefazodone. Clin. Neuropharmacol. 16 (suppl 3), S45-S50 (1993).
66. Shukla U.A., Shea J.P., Gammans R.E.: Single and multiple dose pharmacokinetics of nefazodone and two metabolites in healthy volunteers. Clin. Pharmacol. Ther. 47, 205 (1987).
67. Data on file: Bristol-Myers Squibb Company; Princeton, NM, 1992.
68. Fontaine R., Ontiveros A., Elie R., Kensler T.T, Roberts D.L.etal.:A double-blind comparison of nefazodone, irnipramine, and placebo in major depression. J. Clin. Psychiatry 55, 234-241 (1994).
69. Rickels K., Schweizer E., Clary C. et al.: Nefazodone and imipramine in major depression: a placebo-controlled trial. Br. J. Psychiatry 1644, 802-805 (1994).
70. Armitage R., Rush A.J., Trivedi M., Cain J., Roffwarg H.P.: The effects of nefazodone on sleep architecture in depression. Neuropsychopharmacol. 10, 123-127 (1994).
71. Ware J.C., Rose F.V., McBrayer R.H.: The acute effects of nefazodone. trazodone, and buspirone on sleep and sleep-related penile tumescence in normal subjects. Sleep 77(6). 544-550 (1994).
72. Prange A.J., Wilson I.C., Lynn C.W. et al.: L-tryptophan in mania. Arch. Gen. Psych. 30, 56-62(1974).
73. Vetulani J., Stawarz R.J., Dingell J.V. et al.: A possible common mechanism of action of antidepressant treatments reduction in the sensitivity of the noradrenergic cyclic AMP generating system in the rat limbic forebrain. Naunyn-Schmiedeberg's Arch. Pharmacol. 293, 109-114 (1976).